HPS Pharmacies wish to advise that iNova Pharmaceuticals is experiencing a supply interruption for Mestinon® as follows:
Mestinon® Tablets
Pyridostigmine bromide 60mg
ARTG 13748
Mestinon® Timespan Tablets
Pyridostigmine bromide 180mg
ARTG 13749
Normal supplies of Mestinon® 60mg tablets are expected by end-January 2023; supplies of Mestinon® Timespan 180mg tablets are expected in late March 2023. Mestinon® 10mg tablets are not affected by this supply interruption.
Internationally registered brands of pyridostigmine 60mg tablets and pyridostigmine 180mg controlled-release tablets have been approved for supply under Section 19A of the Therapeutic Goods Act 1989.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact iNova Pharmaceuticals on 1800 630 056 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates